Sanat Chattopadhyay - Merck President
| MRK Stock | MXN 2,176 56.07 2.65% |
President
Mr. Sanat Chattopadhyay is the Executive Vice President and President Merck Manufacturing Division of the Company. He joined Merck in 2009 and currently serves as senior vice president of Global Manufacturing Operations . He was instrumental in transforming Merck Vaccines manufacturing and supply to grow and globalize the company vaccines business. Chattopadhyay also played a key part in leading the company launch of KEYTRUDA in record time by mobilizing a crossdivisional effort to overcome commercialization and supply constraints. since 2016.
| Age | 58 |
| Tenure | 8 years |
| Phone | 908 740 4000 |
| Web | https://www.merck.com |
Merck Management Efficiency
The company has return on total asset (ROA) of 0.1268 % which means that it generated a profit of $0.1268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.351 %, meaning that it generated $0.351 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Dale Smith | First Republic Bank | N/A | |
| Matthew Mandino | KB Home | 53 | |
| Olga Tsokova | First Republic Bank | 50 | |
| David Lichtman | First Republic Bank | 60 | |
| Dianne Snedaker | First Republic Bank | N/A | |
| Pierre Bruno | DXC Technology | N/A | |
| Shannon Houston | First Republic Bank | N/A | |
| James Smith | DXC Technology | N/A | |
| Michael Klaus | DXC Technology | N/A | |
| Eugene OCallaghan | DXC Technology | N/A | |
| Arthur Wong | DXC Technology | N/A | |
| Thomas Norton | KB Home | 52 | |
| Adam Hieb | KB Home | N/A | |
| Justin Gibson | First Republic Bank | N/A | |
| William Deckelman | DXC Technology | 65 | |
| Christopher Newkirk | Capital One Financial | 47 | |
| Michael Harrington | First Republic Bank | N/A | |
| Kelly Johnston | First Republic Bank | N/A | |
| Jason Bender | First Republic Bank | 47 | |
| Stephen Hilton | DXC Technology | 47 | |
| Seelan Nayagam | DXC Technology | N/A | |
Management Performance
| Return On Equity | 0.35 | |||
| Return On Asset | 0.13 |
Merck Company Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Glocer, Independent Director | ||
| Craig Thompson, Independent Director | ||
| Cristal Downing, Ex Officer | ||
| Jennifer Zachary, General Counsel | ||
| Rochelle Lazarus, Independent Director | ||
| Michael Rosenblatt, Executive Vice President Chief Medical Officer | ||
| Wendell Weeks, Independent Director | ||
| Michael Holston, Executive Vice President Chief Ethics and Compliance Officer | ||
| Paul Rothman, Director | ||
| Mary Coe, Director | ||
| Adele Ambrose, Senior Vice President Chief Communications Officer | ||
| Caroline Litchfield, Ex CFO | ||
| Joseph Romanelli, IR Contact Officer | ||
| Mirian GraddickWeir, Executive Vice President - Human Resources | ||
| Peter Wendell, Independent Director | ||
| John Noseworthy, Independent Director | ||
| Jennifer Mauer, VP Communications | ||
| Leslie Brun, Independent Director | ||
| Julie Gerberding, Executive Vice President - Strategic Communications, Global Public Policy & Population Health | ||
| Inge Thulin, Director | ||
| Pamela Craig, Director | ||
| Patricia Russo, Independent Director | ||
| David Williams, Ex Officer | ||
| Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division | ||
| Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller | ||
| Lisa LeCointeCephas, VP Officer | ||
| Robert Davis, CFO and Executive VP | ||
| Robert Kidder, Independent Director | ||
| Thomas Cech, Independent Director | ||
| Michael Nally, Chief Marketing Officer | ||
| Peter Dannenbaum, VP Relations | ||
| Clark Golestani, Executive Vice President CIO | ||
| William Harrison, Lead Independent Director | ||
| Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories | ||
| Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer | ||
| Steven Mizell, Chief Human Resource Officer | ||
| Jim Scholefield, Chief Information and Digital Officer | ||
| Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division | ||
| Adam Schechter, President of Global Human Health and Executive VP | ||
| Carlos Represas, Independent Director | ||
| Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | ||
| Kenneth Frazier, Chairman, CEO and Pres | ||
| Frank Clyburn, Chief Commercial Officer | ||
| Robert JD, Pres Chairman |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.35 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.24 % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 5.9 T | |||
| Shares Outstanding | 2.54 B | |||
| Shares Owned By Insiders | 0.10 % | |||
| Shares Owned By Institutions | 76.37 % | |||
| Price To Earning | 469.71 X | |||
| Price To Book | 6.28 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Merck in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Merck's short interest history, or implied volatility extrapolated from Merck options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Merck Stock analysis
When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |